Alterity Therapeutics Ltd ADR ATHE
Trading Information
- Previous Close Price
- $3.90
- Day Range
- $3.89–4.07
- 52-Week Range
- $2.66–7.00
- Bid/Ask
- $3.89 / $4.17
- Shares Outstanding
- 18.13M
- Market Cap
- $70.69M
- Volume/Avg
- 11,546 / 19,867
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Alterity Therapeutics Ltd is a clinical-stage biotechnology company focused on neurodegenerative diseases and the creation of a chemical library of proprietary molecules. Its research and clinical development efforts are focused on Parkinson’s disease and related disorders, where it is identifying and developing novel compounds that address the underlying pathology of these disorders by binding and redistributing excess labile iron, reducing alpha-synuclein aggregation, and rescuing neurons in the brain. Its pipeline programs are ATH434-201, ATH434-202, bioMUSE, ATH434, and Drug Discovery. The Group operated in one segment, research and development into Parkinsonian and other neurodegenerative disorders.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 9
Valuation
|
Metric
|
ATHE
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.19 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ATHE
|
|---|---|
Quick Ratio | 21.68 |
Current Ratio | 21.98 |
Interest Coverage | — |
Quick Ratio
ATHE
Profitability
|
Metric
|
ATHE
|
|---|---|
Return on Assets (Normalized) | — |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
ATHE
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Vxkbkrkj | Fhkmv | $113B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Jvhdqhg | Lvzvnw | $67B | |||
| argenx SE ADR
ARGX
| Cjhsnlswq | Sxs | $55B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Lgddzrnt | Pmwth | $40B | |||
| Royalty Pharma PLC Class A
RPRX
| Mztpsswb | Pjsfxj | $25B | |||
| BioNTech SE ADR
BNTX
| Fqxbdbbls | Kxrkm | $22B | |||
| Incyte Corp
INCY
| Xvcyhgqq | Pnbf | $20B | |||
| Moderna Inc
MRNA
| Xydvxkgl | Mdfn | $19B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| Kgvxryw | Jczj | $15B | |||
| BridgeBio Pharma Inc
BBIO
| Xcsnvqfy | Dlwkf | $13B |
United States